AVXL Projected Dividend Yield

Anavex Life Sciences Corp ( NASDAQ : AVXL )

Anavex Life Sciences is a clinical stage biopharmaceutical company engaged in the development of therapeutics by applying medicine to central nervous system diseases. Co.'s proprietary SIGMACEPTOR™ Discovery Platform produced small molecule drug candidates with certain modes of action, based on its understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer's disease, as well as of neurodevelopmental nature, like Rett syndrome. Compounds that have been subjects of Co.'s research include the following: ANAVEX®2-73 (blarcamesine), ANAVEX®3-71, ANAVEX®1-41, and ANAVEX®1066, ANAVEX®1037.

20 YEAR PERFORMANCE RESULTS